In silico– tag –
-
bioRxiv Unveils Joint Transcriptomic and Morphological Phenotype Modeling for Generative Molecular Design
bioRxiv International Overview A bioRxiv preprint details research on jointly modeling transcriptomic and morphological phenotypes for generative molecular design. This novel approach allows for the simultaneous consideration of gene exp... -
Converging Frontiers: MDPI Highlights Fusion of Synthetic and Natural Drug Research Reshaping Drug Discovery and DDS
MDPI Switzerland Overview An MDPI review highlights the convergence of synthetic chemistry and natural product research, alongside advancements in pharmaceutical engineering, biomaterials science, computational biology, and translational... -
HKeyBio Launches HKEY-AI2Vivo™ 1.0 Program to Accelerate In Vivo Validation for AI-Designed Candidates, Addressing Pre-IND Bottlenecks
Drug Discovery Online USA Overview HKeyBio launched HKEY-AI2Vivo™ 1.0, an AI Candidate In Vivo Validation Acceleration Program, to support AI drug discovery teams in translating AI-generated targets and molecules into in vivo pharmacolog... -
Machine Learning Accelerates Lipid Nanoparticle Design, Streamlining RNA Therapeutic Formulation Development for High Efficacy and Reduced Experimental Burden
Pharmatica USA Overview Machine learning (ML) is being applied to lipid nanoparticle (LNP) design to accelerate formulation development, improve delivery performance, and reduce experimental burden for RNA therapeutics, gene-editing syst... -
AlphaFold2’s Protein Structure Prediction Breakthrough Earns Nobel Prize, Igniting New Era in AI-Driven Drug Discovery
Facebook (Singularity University) UK Overview Google DeepMind's AlphaFold achieved a groundbreaking advance in protein structure prediction in 2020, leading to a Nobel Prize in 2024 for David Baker, Demis Hassabis, and John Jumper. This ... -
Agentic and Generative AI to Revolutionize Cardiovascular Drug Discovery
American Heart Association Journals USA Overview Large Language Models (LLMs) and agentic AI are poised to fundamentally transform cardiovascular disease (CVD) drug development by enhancing target understanding, accelerating novel compou... -
AI Accelerates Next-Gen Drug Design: From De Novo Protein Creation to Optimized Clinical Trials
SiTech Blog (MIT Technology Review analysis) USA Overview Artificial intelligence is revolutionizing drug discovery by enhancing every stage from protein structure prediction to clinical trial optimization. Generative models like RFdiffu... -
Verseon Champions Physics-Based Molecular Design to Transcend AI’s Training Data in Drug Discovery
Endpoints News USA Overview Verseon asserts that physics-based molecular design can reach chemical spaces beyond the limitations of traditional screening and generative AI training data, opening untapped drug discovery realms. Their Deep... -
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
CoCoGraph: AI System Unleashes Millions of Novel Molecules, Reshaping Drug Discovery and Materials Science
The Daily Guardian Spain Overview Spanish researchers have introduced CoCoGraph, an AI system powered by graph neural networks that can generate millions of novel, chemically valid molecules. Published in *Nature Machine Intelligence*, t...
